focus -WSS

focus

author：fashion 2025-10-02 17:21:16 - browse：6

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Readout LOUD podcast: brain research, obesity drug sales, Novartis

WSS

FDA's Woodcock to retire early next year

Hospitals look to new technology to keep health care workers safe

Congress must reauthorize a committee to support older Americans

Use wet bulb globe temperature, not heat index, to protect workers

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

After gene therapy, two congenitally deaf children hear for the first time

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Tori Bowie and the unacceptable rates of Black maternal death

Google says AlphaFold 3 can map a vast universe of biomolecules

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Psychedelics group wrestles with new pharma identity

Astellas still sees hope in its gene therapy after four deaths

Virginia high school admissions case could be legal follow

First recipient of genetically engineered pig kidney has died

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Wikipedia

Medicare says breakthrough device reimbursement rule to come by summer

Google says AlphaFold 3 can map a vast universe of biomolecules

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

In key trial, Verve's treatment lowers cholesterol levels in patients

Surge of respiratory disease in China has likely explanation

Readout LOUD podcast: What to know about H5N1 bird flu

focus

hotspot

focus

Wikipedia